-free survival; HCM, nonobstructive form of hypertrophic cardiomyopathy; HOCM, obstructive form of hypertrophic cardiomyopathy; HCM/HOCM, combined HCM and HOCM cohort; IQR, interquartile range; LAFB, left anterior fascicular block; LV, left ventricular; LVOTO, LV outflow tract obstruction; NA, not estimable; PES, post-event survival; RBBB, right bundle branch block; RV, right ventricular; SAM, systolic anterior motion of mitral valve; SD, sudden death; SBP, systolic arterial blood pressure; VPCs, ventricular premature complexes .
| I N TR ODU C TI ON
Cardiomyopathies are the principal cause of cardiovascular morbidity and mortality in cats, [1] [2] [3] [4] [5] [6] and hypertrophic cardiomyopathy is the most common of these disorders. Although the majority of affected cats are assumed to remain preclinical (ie, free of clinical signs), a proportion experiences serious complications, chief among which are congestive heart failure (CHF), arterial thromboembolism (ATE), and sudden cardiac death (SD). 2, 5, [7] [8] [9] [15] [16] [17] [18] [19] [20] 25, 26, 28 Certain breeds including Maine
Coon, Ragdoll, British shorthair, Sphynx, Chartreux, Persian, Domestic Shorthair, and Norwegian Forest Cats are predisposed to hypertrophic cardiomyopathy, suggesting a heritable basis in these populations. [10] [11] [12] 24, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Despite the fact that this disease is widely recognized, risk of attendant cardiovascular complications is unknown, and the natural history of preclinical feline hypertrophic cardiomyopathy remains unresolved.
Many phenotypic and clinical characteristics of feline hypertrophic cardiomyopathy, including a highly variable disease course, closely resemble those reported in humans. 2, [7] [8] [9] 15, [21] [22] [23] [24] [25] [26] 28, 29 Whereas the obstructive form of the disease (HOCM) in humans is a major determinant of negative outcome including progressive cardiovascular disability, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] equivalent risk has not been established in affected cats.
Nevertheless, by inference drawn from data in humans, the notion has lingered that HOCM confers a similar negative prognosis in cats and, by extension, signifies a target for pharmacotherapy. 49 Descriptions of cardiovascular complications in cats with hypertrophic cardiomyopathy have originated predominantly from single-site referral centers. 5, 7, 9, [17] [18] [19] [20] 25, 26, 28, 29 Although informative, such results tend to concentrate severely affected cases and are subject to tertiary center referral bias. This can lead to overstating adverse outcomes and fosters the impression that the disease is dominated by pessimistic outcome. 46 Furthermore, combining preclinical and heart failure patient data limits risk estimation and prognosis for cats having only preclinical disease. 5, 7, 9, 14, 17, 26, 28 Thus, to understand the natural history of preclinical hypertrophic cardiomyopathy, we conducted a long-term multicenter, epidemiologic study to evaluate large cohorts of affected and nonaffected cats in many different countries around the world. This approach permitted us to identify and compare incidence and risk for cardiovascular morbidity, mortality, and survival characteristics among these populations.
| M A TE RI A L S A ND M E TH ODS

| Study design
The "International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study" was a retrospective, longitudinal, cohort study. An ethical review committee granted approval where required. Investigators were board-certified veterinary cardiologists, or in countries without a certification process, focused on specialty cardiology practice. Each study site had a searchable echocardiographic and medical record database permitting detailed review and long-term health follow-up.
| Cats
Cat populations included preclinical obstructive (HOCM) and nonobstructive (HCM) forms of hypertrophic cardiomyopathy, and apparently healthy cats (AH). The term preclinical denoted a physical condition characterized by lack of clinical signs or manifestations and would be referred to as "asymptomatic" in human medicine. All AH were examined by echocardiography, had unremarkable medical history, no known illness, and had normal physical examination findings without gallop heart sounds at the point of study entry. Some had been examined by echocardiography due to presence of a systolic heart murmur, but those with a systolic heart murmur, trivial mitral or tricuspid valve regurgitation, or dynamic right ventricular (RV) outflow tract obstruction were included, provided that the echocardiogram was otherwise normal.
| Inclusion criteria
Medical records were searched for cats diagnosed with preclinical hypertrophic cardiomyopathy (both HCM and HOCM) as well as AH free of cardiomyopathy, the health outcomes of which could be ascertained for at least 5 years after initial diagnosis. Archived echocardiographic images were examined to confirm diagnosis and measurements. Study entry represented the date when echocardiographic examination was first made.
| Exclusion criteria
Cats were not included in the study if echocardiograms were of non- 
| Echocardiography
Investigators were instructed to enter cats that had diagnostic-quality 2-dimensional, color flow Doppler, and M-mode echocardiographic examinations performed in accordance with published standards. 8, 50, 51 Diagnosis was based on information from all available tomographic views including right parasternal long-axis 4-chamber, long-axis inflowoutflow, and short-axis views, and left apical views. Cardiac measurements were made from 2D echo-guided M-mode images from right parasternal short-axis views by most investigators or, using 2D echocardiography by several investigators. Left ventricular (LV) hypertrophy was diagnosed when the thickest end-diastolic interventricular septal, LV free wall segment or both measured 6 mm. 8 The obstructive form (HOCM) was defined for our study as LV hypertrophy with systolic anterior motion of the mitral valve (SAM), coupled with diffuse LV outflow tract turbulence and peak systolic outflow velocity 2.5 m/s.
Cases were not stratified according to LV outflow tract gradient.
Dynamic RV outflow tract obstruction was designated when maximal RV outflow tract velocity was > 1.6 m/s. 52 comorbidity type was censored after 1, 5, and 10 years, respectively, allowing for a cross-sectional view of the respective time points. Duration of event-free survival (EFS) comprised the time interval from the date of study entry to the date of first cardiac morbidity (CHF or ATE).
| Data collection and outcomes assessment
Postevent survival (PES) comprised the time from the date of first CHF or ATE morbidity to cardiac death from CHF, ATE, or SD. Additional analyses included stratification at age quartile determined by age at diagnosis. Because of varied study enrollment and study end dates, mean between-cohort survival times estimated by univariate Kaplan
Meier method were used to calculate time to event for EFS and PES, and compared by ANOVA. All analyses were carried out with SAS 9.4
(Cary, NC 2016) and deemed significant at P < .05.
| R E SU LTS
| Population characteristics at time of diagnosis
One-thousand seven-hundred thirty cats fulfilled entry criteria; 1008 (58.3%) had hypertrophic cardiomyopathy comprising 430 (24.9%)
HCM and 578 (33.4%) HOCM; and, 722 (41.7%) were AH (Table 1) .
Apparently healthy cats were younger (median, 4.9 years; range, 0.5-21 years) than HCM (median, 7.4 years; range, 0.5-20 years; P < .001) and HOCM (median, 5.7 years; range, 0.5-19 years; P < .013); HOCM were younger than HCM (P < .001). Ages recorded in 1006 of 1008 HCM/HOCM cats clustered predominantly at 1-5 years and 5-11
years, but the proportion markedly decreased after 11 years of age ( Figure 1 ). Twenty-seven percent were 10 years of age and 10%
were 13-20 years of age. Body weight in HCM and HOCM cats did not differ (P 5 .095), but was slightly higher compared with AH (both P < .001; Table 1 ). The overall study population included 34 breeds, (Table 1) .
Systolic heart murmurs were detected commonly ( Figure 3 ).
The proportion of syncopal events was not different between HCM (n 5 9, 2.1%) and HOCM (n 5 14, 2.4%; P 5 0.838). Syncope was recorded in 2 (0.28%) AH. 
| Incidence
The incidence of CHF, ATE, SD, and all-cardiovascular death events per 1000 cat years for each cohort was delineated by quartiles corresponding with age at the time of study entry (group 1, < 2.5 years; group 2, 2.5-5.6 years; group 3, > 5.6-10 years; group 4, >10 years; Table 4 ). In the HCM/HOCM population, CHF incidence was 24.8% higher in cats > 10 years of age compared to cats < 2.5 years of age (68.1 events versus 51.2 events per 1000 cat years, respectively). The incidence of ATE increased from the first to the third age quartile (from 22.5 to 32.7 events per 1000 cat years, respectively), and then decreased sharply to 18.4 events per 1000 cat years in cats > 10 years of age.
Incidence of cardiovascular death was 57.1 events per 1000 cat years Abbreviations: ATE, arterial thromboembolism; CHF, congestive heart failure; HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.
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| Risk
The risk of cardiovascular morbidity and mortality for HCM, HOCM, and HCM/HOCM cohorts increased progressively at 1, 5, and 10-year intervals after study entry, as well over age quartiles (Table 5 , Figure 4 ).
Of the 1008 cats with preclinical HCM/HOCM, the risk for CHF and ATE morbidity and all-cardiovascular death was approximately 3 times (Table 5 and Figure 4 ). Figure 5 ). The oldest 10% of surviving HCM/HOCM cats at study end were 9-14.7 years of age. Cardiovascular survival was not significantly different between HCM (10.9 years; 2 days-12.5 years) and HOCM (NA; 3 days-13.1 years) over time (P 5 .873; Figure 6 ).
| Survival analyses-mortality
Furthermore, no significant difference was found between HCM and HOCM populations for the overall proportion of cardiovascular death (P 5 .535), proportion of cardiovascular death associated with CHF (P 5 .834), and proportion of cardiovascular death associated with ATE (P 5 .118). Figure 8 ).
| Post-event survival
Post-event survival (the time from onset of CHF or ATE to cardiovascular death) calculated for the 119 cats that survived > 1 day after CHF or ATE had occurred was 1.3 6 1.7 years, significantly shorter than both the EFS for this cohort (P < .0001), and for EFS of the cohort of 140 cats that died on the day of their first cardiovascular morbidity (P < .0001; Figure 8 ). Moreover, PES in these 119 cats did not differ significantly with respect to age quartiles (P 5 .402) or between HCM and HOCM cats that comprised this cohort (P 5 .364).
| D ISC USSION
REAL is the first international, collaborative, epidemiologic study to evaluate populations of preclinical feline hypertrophic cardiomyopathy and AH. Intending to identify and compare long-term cardiovascular incidence, risk, and survival, REVEAL documented the natural history of cats living in geographically diverse environments, in 21 countries, and across 5 continents. In this population, the incidence of cardiovascular morbidity and mortality in affected cats was FIGURE 8 Kaplan-Meier survival curves estimating the EFS proportion and PES proportion (Y-axis) against time (X-axis). Eventfree survival group-A comprised a cohort of 140 cats with preclinical hypertrophic cardiomyopathy who died on the day of their first recorded CHF/ATE morbidity. Event-free survival group-B comprised a cohort of 119 cats with preclinical hypertrophic cardiomyopathy who survived more than one day after their first recorded CHF/ATE morbidity. Postevent survival was calculated for these 119 cats. *P 5 .101; **P < .0001; SD, standard deviation is not a predictor of adverse outcome. 16, 18 This finding diverges from the idea that LVOTO carries high risk for progressive heart failure and the cardiac debilitation that characterizes HOCM in human patients. 39, [43] [44] [45] [46] [47] [48] Reports comparing cardiovascular survival between preclinical feline HCM and HOCM have been sparse, conflicting, and confined to small cohorts. 8, 17 The REVEAL study demonstrated no significant difference in cardiovascular morbidity or survival between HCM and HOCM and should thus help resolve this debate. In reality, the notion that HOCM conferred proportionately higher risk was shaped by the dominance of human literature reporting poor outcomes associated with LVOTO and increased gradients. The REVEAL study found that CHF incidence increased slightly from youngest to oldest age, whereas ATE incidence increased up through the third age quartile, but became less common after the age of 10 years. Risk for CHF, ATE, and cardiovascular death increased over time and age. Moreover, the risk of cardiovascular death for each age quartile was progressively higher at 5 and 10 years compared with 1 year after diagnosis for each age quartile. In AH the risk of cardiovascular death was only 1%. In preclinical HCM and HOCM, sudden death was substantially lower in our present study than described from mixed preclinical and clinical feline populations. 8, 9, 18, 25, 28 Sudden death is a well-known manifestation of hypertrophic cardiomyopathy in humans, especially in high risk subgroups. [46] [47] [48] Early onset of preclinical HCM or HOCM, defined as occurring in cats < 1 year of age was approximately 3% in the HCM/HOCM cohort in our study. Other reports of early onset vary widely based on cut-off values used to define LV end-diastolic wall thickness. 10, 12, 24, 28, 37 Age of hypertrophic cardiomyopathy associated with cardiovascular death has been reported in certain breeds, including young, highly inbred Maine
Coon cats, particularly in litters where affected individuals were mated. 24 In addition, Ragdoll cats homozygous for the MYBPC3 R820W mutation died at a younger age and cardiovascular survival was shorter compared to heterozygous or wild types, 32 and onset of CHF before 1 year of age has been observed in this breed. 53 Others have reported that the age at which cardiovascular morbidity developed was younger in Maine Coon than Persian, DSH, Sphynx, and Chartreux breeds combined. 28 Preclinical HCM/HOCM in our study was diagnosed most commonly between 1 and 11 years of age, and the proportion decreased sharply thereafter. Others have reported wide age variability from pooled preclinical and clinically affected populations. [7] [8] [9] 12, 18, 25, 26, 54 Of the HCM/HOCM cats that developed CHF or ATE, the mean EFS did not exceed 3 years. In addition, EFS did not differ significantly between HCM and HOCM populations. Thus, once affected cats developed cardiovascular morbidity, the trajectory of PES from onset of clinical signs to cardiovascular death was rapid, averaging just 1.3 years.
Although hypertrophic cardiomyopathy has been held to presage decreased survival, REVEAL found that a proportion of affected cats survived into their second decade. Similar findings have been reported in selected pedigrees in which nearly one-third were 10-15 years of age and approximately 5% were > 15 years of age. 28 This finding indicates that preclinical hypertrophic cardiomyopathy can be compatible with normal life expectancy. Prolonged survival with this condition has been increasingly reported in affected humans. 46 The HCM/HOCM population's high male prevalence, dominated by neutered males, was similar to previously reported male predilection rates of between 63% and 79%. 7, 9, 13, 17, 18 Heart murmurs were com- was not possible to determine whether a subset of cats with high gradients is at higher cardiovascular risk. Although we attempted to exclude cats with known underlying diseases in preclinical hypertrophic cardiomyopathy and AH cohorts, some may have had undiagnosed or preclinical conditions. A standardized medical questionnaire was used to aid data collection when interviewing clients and referring veterinarians, but some details may have been incorrectly remembered or missed. Assessment of treatment compliance and potential drug effects was not possible in this retrospective study.
| CON CL U S I ONS
Data from the REVEAL study demonstrates that preclinical feline hypertrophic cardiomyopathy is a global health concern that imposes considerable risk for CHF and ATE morbidity, and substantially impacts cardiovascular health over time. Indeed, cardiovascular morbidities were recorded in nearly one-third and cardiovascular-related death occurred in approximately 30% of the 1008 cats with HCM and HOCM. There was no statistically significant difference between obstructive (HOCM) and nonobstructive (HCM) forms of hypertrophic cardiomyopathy regarding cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival.
Collectively, these epidemiologic data highlight cardiovascular risks associated with preclinical hypertrophic cardiomyopathy, and
